Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

2 of 0 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 2

4(50.0%)

8Total

Phase 1(4)

Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03132922Phase 1Active Not Recruiting

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Role: lead

NCT03967223Phase 2Active Not Recruiting

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Role: lead

NCT06703346Phase 2Active Not Recruiting

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Role: lead

NCT03391778Phase 1Recruiting

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Role: lead

NCT05601752Phase 2Active Not Recruiting

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Role: lead

NCT06617572Unknown

Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

Role: lead

NCT05642455Phase 1Recruiting

SPEARHEAD-3 Pediatric Study

Role: lead

NCT04044859Phase 1Active Not Recruiting

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Role: lead

NCT04044768Phase 2Active Not Recruiting

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Role: lead

All 9 trials loaded